{"id":"captopril-and-trandolapril","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Dry cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"0.1-0.5","effect":"Angioedema"},{"rate":"5-10","effect":"Hypotension"},{"rate":"3-5","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ACE inhibitors block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, resulting in lower blood pressure and reduced cardiac workload. These agents are commonly used in hypertension and heart failure management.","oneSentence":"Both captopril and trandolapril inhibit angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:46.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Post-myocardial infarction"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT01669434","phase":"PHASE4","title":"Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-06-01","conditions":"Hypotension on Induction","enrollment":291},{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":"Heart Diseases, Diabetes Mellitus, Type 2","enrollment":2400},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT01867047","phase":"NA","title":"ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients","status":"TERMINATED","sponsor":"Duke University","startDate":"2013-06","conditions":"Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension","enrollment":59},{"nctId":"NCT01437371","phase":"PHASE3","title":"Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2011-08","conditions":"Heart Failure","enrollment":35},{"nctId":"NCT00391846","phase":"PHASE4","title":"Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-10","conditions":"Heart Failure, Ventricular Dysfunction, Left","enrollment":252},{"nctId":"NCT00252317","phase":"PHASE4","title":"Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2005-11","conditions":"Aortic Stenosis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":63,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Captopril and Trandolapril","genericName":"Captopril and Trandolapril","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Captopril and Trandolapril are both Angiotensin-Converting Enzyme Inhibitors (ACEIs), which are used to treat conditions such as hypertension and heart failure. They work by inhibiting the conversion of angiotensin I to angiotensin II, a mechanism that is also targeted by other drugs like Sacubitril/Valsartan.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}